Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T49040
(Former ID: TTDI01254)
|
|||||
Target Name |
Glucose metabolism (Glucose metab)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Metabolic disorder [ICD-11: 5C50-5D2Z] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | INS-1 | Drug Info | Phase 2 | Metabolic disorder | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | INS-1 | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Herbal constituent sequoyitol improves hyperglycemia and glucose intolerance by targeting hepatocytes, adipocytes, and beta-cells. Am J Physiol Endocrinol Metab. 2012 April 15; 302(8): E932-E940. | |||||
REF 2 | ClinicalTrials.gov (NCT00349726) Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.